Drug Costs Are Spiking and It’s Not Clear Why

Pharmacists want Congress to investigate a sharp increase in medicinal costs.

A pharmacist pours Truvada pills back into the bottle at Jack's Pharmacy on November 23, 2010 in San Anselmo, California.
National Journal
Clara Ritger
Add to Briefcase
See more stories about...
Clara Ritger
Jan. 31, 2014, 12:05 a.m.

Drug costs are rising, but in the opaque world of health care pri­cing, fig­ur­ing out what’s driv­ing the in­crease has be­come dif­fi­cult — if not im­possible.

Non­ethe­less, phar­macists want Con­gress to try. Vexed by triple- or quad­ruple-di­git per­cent in­creases in drug costs, the Na­tion­al Com­munity Phar­macists As­so­ci­ation is ask­ing law­makers to hold a hear­ing to find out why.

The prob­lem, the group says, is that phar­macists are get­ting gouged. Phar­macists try­ing to get their hands on gen­er­ic drugs such as Pravast­at­in, a drug for pa­tients with high cho­les­ter­ol, or the an­it­bi­ot­ic Doxy­cyc­line faced price spikes up­wards of 1,000 per­cent in 2013, ac­cord­ing to a sur­vey by the group.

Some 77 per­cent of phar­macists sur­veyed by the as­so­ci­ation said in the last six months of 2013 they ex­per­i­enced 26 or more in­stances of a large up­swing in the ac­quis­i­tion price of a gen­er­ic drug.

An ad­di­tion­al 84 per­cent said the price fluc­tu­ations im­peded their abil­ity to provide care and re­main in busi­ness, as some com­munity phar­ma­cies could not fill pre­scrip­tions that would res­ult in losses and some pa­tients de­clined med­ic­a­tion that would have emp­tied their wal­lets.

The find­ings are con­sist­ent with re­ports na­tion­wide that gen­er­ic-drug prices are ex­per­i­en­cing bank-break­ing price in­creases. Health care and phar­ma­ceut­ic­al con­sult­ing firm Pem­broke Con­sult­ing, for in­stance, found that with­in the last year, more than a dozen drugs hit prices 10 times their stand­ard rate. NCPA wants Con­gress to hold a hear­ing to find out what’s driv­ing the price points and wheth­er any­thing can be done by the feds to stop the trend.

But one primary-care doc­tor, Dav­id Belk, says he’s sus­pi­cious that the fault lies with drug com­pan­ies. The San Fran­cisco-based blog­ger has ob­served price jumps in single doses of med­ic­a­tion, where one size dosage of a drug was very ex­pens­ive and the oth­er dosages of that same drug were at a more reas­on­able cost.

Belk took a clip of the Costco web­site after he saw the gen­er­ic drug Irbe­sartan, a med­ic­a­tion for high blood pres­sure, hit nearly $300 for a 90-day sup­ply of the 150 mg tab­let. Yet for the 90-day sup­ply of the 300 mg tab­let, con­sumers paid only $30.

“If you ask the phar­ma­ceut­ic­al com­pany, they’ll say ‘Oh, we had a short­age,’ ” Belk said, “which makes no sense be­cause they were mak­ing oth­er mil­li­grams. By the time the phar­macy has figured out the price spiked, it’s dropped back down again.”

That trend, Belk said, leaves phar­ma­cies hanging out to dry with the ex­tra cost.

“Most doc­tors are pre­scrib­ing on the basis of the last drug rep they went to lunch with,” he said. “I think you would fix a lot of it if every­one had to ad­vert­ise their price.”

While Belk pro­poses to turn pa­tients in­to edu­cated con­sumers by cre­at­ing trans­par­ency about pre­scrip­tion drug costs at the doc­tor’s of­fice, the prob­lem re­mains that phar­macists can’t place their fin­ger on why gen­er­ic drugs seem to cost more than they used to—or at least, ex­per­i­ence ex­treme price vari­ations throughout the year.

Dan Mendel­son, CEO of con­sult­ing firm Avalere Health, cred­its the ef­fect­ive­ness and pop­ular­ity of gen­er­ic drugs as one reas­on phar­ma­ceut­ic­al com­pan­ies are able to charge more.

“I think that as de­mand for gen­er­ic drugs has gone up, it’s not sur­pris­ing to see that price has gone up as well,” Mendel­son said. “This is an un­reg­u­lated mar­ket in the sense that no one is telling them what to charge. You’re go­ing to see them cozy up to the price of the brand name product for com­pet­i­tion reas­ons.”

Mendel­son said his prob­lem with get­ting Con­gress in­volved in the situ­ation is that it sug­gests they should step in­to the mar­ket and im­pose price con­trols. Some­times, he said, the spikes are eas­ily ex­plained, such as when Doxy­cyc­line ex­per­i­enced a man­u­fac­tur­ing prob­lem and had a tem­por­ary short­age.

“I think people will con­tin­ue to use these gen­er­ic products be­cause they’re cost ef­fect­ive and needed when pre­scribed,” Mendel­son said. “There’s no ques­tion in my mind de­mand is go­ing to go up be­cause of the Af­ford­able Care Act, and these mar­kets re­spond to de­mand.”

Even high­er prices for gen­er­ics could be on the ho­ri­zon, as all health plans offered on the Af­ford­able Care Act ex­changes must cov­er pre­scrip­tion drugs, which could in­crease use and de­mand among con­sumers.

The Af­ford­able Care Act, however, doesn’t in­clude any spe­cif­ic pro­vi­sions to re­duce the over­all cost of drugs. But gen­er­ics are still cheap­er than their brand-name coun­ter­parts. And with more pat­ents for block­buster drugs set to ex­pire by 2018, they’ll con­tin­ue to be a com­pet­it­ive op­tion on the mar­ket.

What We're Following See More »
WITH LIVE BLOGGING
Trump Deposition Video Is Online
15 hours ago
STAFF PICKS

The video of Donald Trump's deposition in his case against restaurateur Jeffrey Zakarian is now live. Slate's Jim Newell and Josh Voorhees are live-blogging it while they watch.

Source:
SOUND LEVEL AFFECTED
Debate Commission Admits Issues with Trump’s Mic
16 hours ago
THE LATEST

The Commission on Presidential Debates put out a statement today that gives credence to Donald Trump's claims that he had a bad microphone on Monday night. "Regarding the first debate, there were issues regarding Donald Trump's audio that affected the sound level in the debate hall," read the statement in its entirety.

Source:
TRUMP VS. CHEFS
Trump Deposition Video to Be Released
16 hours ago
THE LATEST

"A video of Donald Trump testifying under oath about his provocative rhetoric about Mexicans and other Latinos is set to go public" as soon as today. "Trump gave the testimony in June at a law office in Washington in connection with one of two lawsuits he filed last year after prominent chefs reacted to the controversy over his remarks by pulling out of plans to open restaurants at his new D.C. hotel. D.C. Superior Court Judge Brian Holeman said in an order issued Thursday evening that fears the testimony might show up in campaign commercials were no basis to keep the public from seeing the video."

Source:
A CANDIDATE TO BE ‘PROUD’ OF
Chicago Tribune Endorses Gary Johnson
19 hours ago
THE LATEST

No matter that his recall of foreign leaders leaves something to be desired, Gary Johnson is the choice of the Chicago Tribune's editorial board. The editors argue that Donald Trump couldn't do the job of president, while hitting Hillary Clinton for "her intent to greatly increase federal spending and taxation, and serious questions about honesty and trust." Which leaves them with Johnson. "Every American who casts a vote for him is standing for principles," they write, "and can be proud of that vote. Yes, proud of a candidate in 2016."

NEVER TRUMP
USA Today Weighs in on Presidential Race for First Time Ever
1 days ago
THE DETAILS

"By all means vote, just not for Donald Trump." That's the message from USA Today editors, who are making the first recommendation on a presidential race in the paper's 34-year history. It's not exactly an endorsement; they make clear that the editorial board "does not have a consensus for a Clinton endorsement." But they state flatly that Donald Trump is, by "unanimous consensus of the editorial board, unfit for the presidency."

Source:
×